The main task of the NeuroPharm Council of Investigators (COI) group is to coordinate the daily operation of the different NeuroPharm projects in the four work packages. This includes monitoring and discussing research progress and mutually informing about individual project status and discussing practical and scientific aspects of mutual interest. The members of NeuroPharm's COI group are:
|
|
NP1 leader: Vibe G. Frøkjør Neurobiology Research Unit, Rigshospitalet and Psychiatric Centre Copenhagen Vibe G. Frøkjær is a medical doctor with clinical experience in neurology and psychiatry. The last decade she has been involved in brain research based at Neurobiology Research Unit. Her research line aims at uncovering neurobiological correlates to vulnerability for developing neuropsychiatric disease, which ideally hold a preventive potential. She works primarily with molecular imaging of serotonergic neurotransmission in the context of steroid hormone biology, and genetic and personality risk factors for neuropsychiatric disease. |
|
|
NP2 leader: Patrick Fisher Neurobiology Research Unit, Rigshospitalet Patrick Fisher holds a PhD in Neuroscience from the Center for Neuroscience at the University of Pittsburgh (US) and is assisting professor with special focus on multimodal brain imaging. He has been involved in brain research at Neurobiology Research Unit since 2011 and his research focuses on identifying molecular mechanisms that shape inter-individual variability in behaviorally relevant brain function and related risk for psychopathology through multi-modal human neuroimaging, imaging genetics and intervention strategies. |
|
|
NP3 leader: Hanne D. Hansen Neurobiology Research Unit, Rigshospitalet Hanne D. Hansen has a PhD in experimental neuroimaging with special focus on radiotracer evaluation, PET data analysis, and simultaneous PET-MR imaging. During her PhD studies she spent time at the A.A. Martinos Center for Biomedical Imaging in Boston, where she carried out a preclinical project in non-human primates. The results of these studies have laid the foundation for one of the projects in NP3, namely a clinical PET-MR project studying the 5-HT1B receptor and the effects of giving pharmacological interventions. |
|
|
NP4 leader: Brice Ozenne Neurobiology Research Unit, Rigshospitalet and Section of Biostatistics, University of Copenhagen Brice Ozenne is a biostatistician with a PhD from University Lyon 1 (France). He is interested in the development of Latent Variable Models for complex data, predictive models and dimension reduction methods and he is applying these methods on neuroscience data to investigate the relationship between the brain response and depression. In 2017 he was awarded one of the competitive Marie-Curie fellowships. |
